Follow
Andrew M  Davis
Andrew M Davis
AstraZeneca, Fisons, Astra, University of Kent
Verified email at astrazeneca.com
Title
Cited by
Cited by
Year
The design of leadlike combinatorial libraries
SJ Teague, AM Davis, PD Leeson, T Oprea
Angewandte Chemie International Edition 38 (24), 3743-3748, 1999
10191999
Is there a difference between leads and drugs? A historical perspective
TI Oprea, AM Davis, SJ Teague, PD Leeson
Journal of chemical information and computer sciences 41 (5), 1308-1315, 2001
10142001
A comparison of physiochemical property profiles of development and marketed oral drugs
MC Wenlock, RP Austin, P Barton, AM Davis, PD Leeson
Journal of medicinal chemistry 46 (7), 1250-1256, 2003
6232003
Application and limitations of X‐ray crystallographic data in structure‐based ligand and drug design
AM Davis, SJ Teague, GJ Kleywegt
Angewandte Chemie International Edition 42 (24), 2718-2736, 2003
5272003
Hydrogen bonding, hydrophobic interactions, and failure of the rigid receptor hypothesis
AM Davis, SJ Teague
Angewandte Chemie International Edition 38 (6), 736-749, 1999
4871999
Time-related differences in the physical property profiles of oral drugs
PD Leeson, AM Davis
Journal of medicinal chemistry 47 (25), 6338-6348, 2004
3342004
Chemical predictive modelling to improve compound quality
JG Cumming, AM Davis, S Muresan, M Haeberlein, H Chen
Nature reviews Drug discovery 12 (12), 948-962, 2013
2632013
An alternative method for the evaluation of docking performance: RSR vs RMSD
D Yusuf, AM Davis, GJ Kleywegt, S Schmitt
Journal of chemical information and modeling 48 (7), 1411-1422, 2008
2212008
Partitioning of ionizing molecules between aqueous buffers and phospholipid vesicles
RP Austin, AM Davis, CN Manners
Journal of pharmaceutical sciences 84 (10), 1180-1183, 1995
2181995
Limitations and lessons in the use of X-ray structural information in drug design
AM Davis, SA St-Gallay, GJ Kleywegt
Drug discovery today 13 (19), 831, 2008
1812008
Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks™ HT
MH Bridgland-Taylor, AC Hargreaves, A Easter, A Orme, DC Henthorn, ...
Journal of pharmacological and toxicological methods 54 (2), 189-199, 2006
1732006
Components of successful lead generation
AM Davis, DJ Keeling, J Steele, NP Tomkinson, AC Tinker
Current Topics in Medicinal Chemistry 5 (4), 421-439, 2005
1292005
Charge description of base-catalyzed alcoholysis of aryl phosphodiesters: A ribonuclease model
AM Davis, AD Hall, A Williams
Journal of the American Chemical Society 110 (15), 5105-5108, 1988
1171988
Cognitive aspects of recalling and reporting health-related events: Papanicolaou smears, clinical breast examinations, and mammograms
RB Warnecke, S Sudman, TP Johnson, D O'Rourke, AM Davis, JB Jobe
American Journal of Epidemiology 146 (11), 982-992, 1997
1161997
A single transition state in the reaction of aryl diphenylphosphinate esters with phenolate ions in aqueous solution
N Bourne, E Chrystiuk, AM Davis, A Williams
Journal of the American Chemical Society 110 (6), 1890-1895, 1988
1161988
Predictive ADMET studies, the challenges and the opportunities
AM Davis, RJ Riley
Current opinion in chemical biology 8 (4), 378-386, 2004
1132004
Cyber security in new space: analysis of threats, key enabling technologies and challenges
M Manulis, CP Bridges, R Harrison, V Sekar, A Davis
International Journal of Information Security 20, 287-311, 2021
1122021
Drug-like properties: guiding principles for design–or chemical prejudice?
PD Leeson, AM Davis, J Steele
Drug Discovery Today: Technologies 1 (3), 189-195, 2004
1012004
A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries
KK Chohan, SW Paine, J Mistry, P Barton, AM Davis
Journal of medicinal chemistry 48 (16), 5154-5161, 2005
952005
In Silico Human and Rat Vss Quantitative Structure−Activity Relationship Models
MP Gleeson, NJ Waters, SW Paine, AM Davis
Journal of medicinal chemistry 49 (6), 1953-1963, 2006
912006
The system can't perform the operation now. Try again later.
Articles 1–20